29 September 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products, is pleased to announce the Maastricht University Medical Centre (MUMC) in the Netherlands has signed a purchase agreement for Imricor’s consumable products.
To commence procedures as quickly possible, MUMC will utilise an existing diagnostic MRI suite in their facility, while new facilities are being planned and constructed. The site is expected to complete a purchase agreement with Philips for other iCMR capital equipment in the coming days, including Advantage-MR EP Recorder/Stimulator. This will mark the first sale of Imrcior’s capital product under the previously announced non-exclusive Sales Distribution Agreement between Imricor and Philips.
Imricor’s Chair and CEO, Steve Wedan, commented: “We are obviously very excited about the Philips Sales Distribution Agreement, and this sale of our Advantage-MR system to MUMC will serve as a model for execution of that agreement. We expect the broader Philips sales team to be trained on iCMR applications before the end of the year.”
Installation and training at MUMC are currently being planned with first procedures expected to commence in mid-November.
“We’re seeing some tightening of COVID-19 travel restrictions this week,” noted Mr Wedan, “but we are planning with that in mind, and we’re ready to utilise our European-based sales team for installation and training, as we did previously at Haga Hospital and Amsterdam UMC. In addition, unlike the first time COVID-19 struck, we are seeing better readiness and increased desire across all stakeholders to continue advancing medicine and treating non-COVID patients during any virus spikes.”